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Abstract: Two novel silver(I) complexes of the biologically active ligand miconazole in the form
of Ag(MCZ)2X (MCZ = 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole];
X = NO3− (1), ClO4− (2)) were synthesized and fully characterized. The complexes were obtained by
reactions of Ag(I) salts with miconazole (MCZ). Silver(I) complexes were characterized by elemental
analysis, 1H-NMR and infrared (IR) spectroscopy, electrospray ionization (ESI)-MS spectrometry,
and X-ray-crystallography. This work also presents a cytotoxicity study of the silver(I) complexes of
miconazole and appropriate silver(I) salts using Balb/c 3T3 and HepG2 cell lines. The cytotoxicity of the
compounds was assessed based on four biochemical endpoints: lysosomal activity (neutral red uptake
(NRU) assay), mitochondrial activity (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium
bromide (MTT) assay), total protein content (TPC assay), and cellular membrane integrity (lactate
dehydrogenase (LDH) assay). The cancer HepG2 cells were more sensitive to the complexes tested,
and the most affected endpoint was cellular membrane damage compared to Balb/c 3T3 fibroblasts.
Moreover, study complexes inhibited the growth of cancer cells at submicromolecular concentrations
(0.26–0.47 µM) lower than that required for the anticancer agent, cisplatin, in MTT, NRU, and TPC
assays. Both complexes were characterized by higher toxicity to human cancer cells (HepG2) than
silver(I) salts and the free ligand. Combination of Ag(I) salts with miconazole is associated with the
marked improvement of cytotoxic activities that can be considered as the significant point in the
construction of a new generation of antineoplastic agents.
Keywords: silver(I) complex; cytotoxicity; NMR spectroscopy; IR spectroscopy; X-ray crystallography;
Balb/c 3T3 cell line; HepG2 cell line
1. Introduction
Chemotherapeutic agents play a significant role in medicine and veterinary services. Consequently,
many studies aimed at discovering new forms of these agents are being conducted today. The discovery
of new metal complexes, which have innovative therapeutic effects in medical practice, is of great
interest to researchers [1,2]. Moreover, many of them focus on the synthesis of new complexes of
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transition metals that show anticancer properties against various cancer cells [3–10], and they can be
an alternative to chemotherapy that is associated with severe side effects [11].
Cisplatin (cis-diamminedichloroplatinum(II)) is a medicine used against various types of human
cancers such as lung, ovarian, head, bladder, and testicular cancer. However, due to numerous side
effects such as kidney problems, allergic reactions, the development of resistance in cancer cells,
or hemorrhage, its use is limited [12,13].
Silver and its compounds are effective and widely used antimicrobial agents [14–16]. Silver
compounds were used to prevent infections before antibiotics were invented. For this purpose, silver
nitrate solution was most often used, followed by cream containing sulfadiazine silver(I) salts, which
was mainly used for burns. Silver-based compounds are also used in medical devices such as catheters,
implants, and surgical sutures [17,18].
It is proven that many silver complexes showed better biological activity than the free ligand,
which is the basis for their use in medical purposes [19–22].
Silver(I) complexes have a strong antibacterial and antifungal effect, characterized by low toxicity to
humans [23–27]. Recent studies show that silver complexes also have strong anticancer properties [6,28]
and are cytotoxic to various cell types [29,30].
Currently, toxicity testing is a necessary stage in preclinical testing of a potential therapeutic
agent [31–33].
In vivo research is problematic due to related ethical and social issues, as well as legal and
economic concerns. For this reason, in vitro tests are used in many cases to limit animal experimentation.
Cytotoxicity studies may provide reliable and useful information on the potential mechanism of action
due to the fact that the impairment of basic cellular functions results in toxic effects within the whole
organism [34–39].
The Organization for Economic Cooperation and Development (OECD) recommends a Balb/c 3T3
cell line for testing the overall toxicity of chemicals [36]. In the case of cancer patients, HepG2 cells are
widely used as a test system to predict toxicity. They are used as target cells in the evaluation of liver
cancer toxicity in humans [40].
Miconazole (MCZ) is a drug used in medicine with antifungal activity [41–44]. The chemical
structure of miconazole is presented in Figure 1. It is a white powder, soluble in ethanol, hardly soluble
in methanol, and practically insoluble in water. It is used to treat systemic fungal infections such as
candidiasis and to treat skin infections such as dandruff. Miconazole eliminates itching of the skin,
which often accompanies infections caused by yeast and dermatophytes. In addition, the drug has
antibacterial activity against Gram-positive bacteria. It is used in the form of a lotion, cream, powder,
chewing gum, or buccal tablets in the case of oropharyngeal candidiasis [45]. A commonly used drug
with miconazole nitrate (20 mg/1 g) as the active substance is Daktarin® [46].
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have promising therapeutic potential and can be used as antifungal, antibacterial, and anticancer
agents [48]. The synthesis and characterization of silver complexes with benzimidazole derivatives
were also described. The results showed that these compounds have stronger antibacterial and
anticancer properties than the free ligand. In addition, these compounds are not toxic to healthy 10T1/2
cells (murine fibroblasts) [49].
The goal of present study was to develop a fast and simple one-step procedure for the direct
synthesis of new complexes using miconazole, the antifungal synthetic derivative of imidazole which
is used in the treatment of candida skin infections, and silver nitrate, which is used as an anti-infective
agent. The method describes the use of silver(I) nitrate or silver(I) perchlorate and miconazole as
molecules directly forming final complexes.
The compounds were characterized by spectroscopic methods (1H-NMR, infrared (IR)), elemental
analysis, electrospray ionization (ESI)-MS, and X-ray measurements. Additionally, Quantum Theory
of Atoms in Molecules (QTAIM) [50] was employed to analyze two types of chemical bonds:
silver–nitrogen between the silver cation and nitrogen from azole ligands, and silver–oxygen (or fluorine)
between silver(I) and counter anions (NO3−, ClO4−, CF3COO−, CH3SO3−, BF4−).
The aim of the research was also to determine anticancer activity against human hepatocellular
carcinoma. The cytotoxic potential of the compounds was tested against the HepG2 human liver
cancer cell line and murine fibroblast Balb/c3T3 cell line compared to cisplatin, by calculating the half
maximal inhibitory concentration (IC50) for the compounds tested. Indeed, the goal was achieved, and
the results are presented below.
2. Results and Discussion
2.1. Synthesis of the Compounds [Ag(MCZ)2NO3] (1) and [Ag(MCZ)2ClO4] (2)
A complex of miconazole with appropriate silver(I) salts was obtained by reacting the AgX
[X = NO3−, ClO4−] with miconazole (1:2) (Scheme 1) in ethanol. The resulting compound was obtained
with good yield and purity.
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2.2. NMR Spectroscopy
Complexes and free drug spectra were recorded in CDCl3 as the solvent. In the free ligand
spectrum, doublets appeared at 7.26 and 7.27 ppm, which can be attributed to the H4 and H5 protons of
the imidazole ring. Unfortunately, there are no H2-derived signals in the imidazole ring in the CDCl3
solvent. The signals at 7.38 and 7.48 ppm from H3 and H3′ protons appeared on the spectrum. Signals
at 7.32 and 7.33 ppm are also observed and are attributed to H5′ and H6′ protons, while signals at 7.20
and 7.05 ppm are attributed to H5 and H6 protons. The signal at 4.10 ppm can be assigned to aliphatic
CH proton, and signals between 4.08–4.52 ppm may be attributed to two aliphatic CH2 protons [51].
The spectra of silver(I) complexes show slight shifts to a higher field compared to the free
MCZ ligand (Table 1). According to the literature data, slight shifts seem to be typical for silver(I)
complexes [25,52]. In addition, compared to the ligand, the spectra of the complex show signals at
8.08 ppm for compound 1 and 8.20 ppm for compound 2, which is attributed to H2 in the imidazole ring.
The 1H-NMR spectra of the compounds are presented in the (Supplementary Materials Figure S1).
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Table 1. Proton chemical shifts in ppm for miconazole and complex compounds at room temperature
in CDCl3.
Miconazole Ag(MCZ)2NO3 Ag(MCZ)2ClO4
Proton Chemical Shift (ppm) Chemical Shift (ppm) Chemical Shift (ppm)
Imidazole
H2 - 8.08 8.20
H4 7.26 7.32 7.33
H5 7.27 7.34 7.34
2,4-Dichlorophenyl
(Ring I) H3 7.37 7.40 7.40
(Ring I) H5 7.20 7.29 7.29
(Ring I) H6 7.16 7.08 7.09
(Ring II) H3′ 7.49 7.49 7.49
(Ring II) H5′ 7.33 7.37 7.39
(Ring II) H6′ 7.32 7.36 7.35
Aliphatic-CH 4.10 4.16 4.19
2-Aliphatic-CH2 4.27–4.52 4.29–4.55 4.32–4.56
2.3. IR Spectroscopy
Infrared spectroscopy was used to confirm the formation of a coordination bond between the metal
and the organic ligand and to confirm the changes occurring as a result of interaction of miconazole
with silver(I) salts.
In the free ligand spectrum, the bands at 1589 and 1562 cm−1 are attributed to C–C stretching
vibrations of the two dichlorobenzene groups. The band at 1505 cm−1 corresponds to C–C stretching
vibrations of the imidazole group and the CH bending of the imidazole group, i.e., the C6 aliphatic part
of miconazole. The band at 1468 cm−1 is attributed to CH bending vibrations of two dichlorobenzene
groups and CH bending of the C6 and C17 [53]. In addition, in the miconazole spectrum, a band
at 3151 cm−1 is observed, which is attributed to the CN vibration of the imidazole group, with the
band at 3109 cm−1 corresponding to aromatic CH stretching, and those at 1380 cm−1 and 1334 cm−1
corresponding to C–H bending and C–N stretching [54].
The silver(I) spectra of the complexes (Supplementary Materials Figure S2) contain characteristic
miconazole vibration bands. These are the C–C stretching vibration bands of two dichlorobenzene
groups that occurr in the IR spectra of the complexes at 1588 (1) and 1590 cm−1 (2), as well as at 1562 (2)
and 1563 cm−1 (1). The band corresponding to the CH bending vibrations of the two dichlorobenzene
groups is located in the spectra of the complexes at 1470 (2) and 1471 cm−1 (1), respectively. The
band at 1092 cm−1 on the spectrum of the free drug corresponding to the stretching vibrations of the
C–O–C group is found in the obtained coordination compounds at 1095 cm−1 for compound 1 and at
1098 cm−1 for compound 2. This band remains intact in solid complexes, indicating its noninvolvement
in metal ion coordination. The bands at 1722 cm−1 for 1 and 1727 cm−1 for 2 appear on the spectra
of the complexes. This band is not present in the spectrum of the free ligand. Due to the lack of
literature, it can be assumed that these bands come from the C=N group of stretching vibrations
of the imidazole nitrogen. The presence of these bands in comparison to the miconazole spectrum
indicates the coordination of the drug with silver(I) ions by the imidazole group nitrogen atom, which
is confirmed by the X-ray structural studies of the obtained single crystals of the complexes. In addition,
all peaks recorded on the spectra of the complexes are more intense compared to the free drug.
2.4. Light Stability of the Compounds
The light stability of the [Ag(MCZ)2NO3] and [Ag(MCZ)2ClO4] complexes and silver(I) salts
(AgNO3, AgClO4) was studied in normal daylight in air atmosphere and in the dark [20,55].
The 0.05 mol/L solutions of the compounds were applied onto the following backgrounds: tissue
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paper, paper, glass, and synthetic leather. Stability was monitored visually for 108 h, making image
documentation after 0, 1, 4, 18, 24, 40, 48, 52, 60, 84, and 108 h.
Appropriate silver(I) salts darkened on tissue paper and paper after 1 h of exposure to light.
The complexes remained unchanged until 24 h. The salts of silver(I) completely darkened after 24 h on
all backgrounds. The decomposition of the complex compounds was mild and slightly darkened after
three days. The complexes decomposed most quickly on the leather imitation. On a glass and tissue
paper background, the compounds remained unchanged. A slight darkening of the silver–miconazole
complexes was observed on the paper.
The complexes obtained clearly showed better stability during exposure to light than silver(I) salts.
The experiment which was conducted simultaneously without access to light proceeded as expected.
The complex compounds showed better stability than Ag(I) salts, whereby their decomposition
progressed slower than in the case of exposure to light. Light significantly influences the rate of silver
nitrate decomposition.
The experiment showed that the compounds studied could potentially be used in pharmacy as an
external agent in the form of ointments or gels (Supplementary Materials Figure S3).
2.5. X-ray Single-Crystal Structures
Supplementary crystallographic data for this paper can be found at the Cambridge Crystallographic
Data Center under the depository numbers CCDC 1977953 (1) and 1977954 (2).
The molecular structures of silver(I) complexes of miconazole and two different counter ions,
nitrate (1) and perchlorate (2), are shown in Figure 2. The crystal data are summarized in Table 2.
Both complexes crystallize in a monoclinic system, in the C2/c space group, Z = 4. In both structures,
Ag(I) lies on a two-fold axis and is coordinated by two nitrogen atoms (N2) from symmetrically related
miconazole ligands. Table 3 lists the bond lengths and angles around the silver atom. The silver donor
bond lengths differ significantly. Moreover, the spatial arrangement of miconazole ligands around the
metal atom is also different. The N–Ag–N bond angle is close to be linear in 2 in contrast to strong
bending observed in 1. Furthermore, the two imidazole rings are almost coplanar in 1, and the dihedral
angle between them is 3.0(3)◦, whereas, in 2, the five-membered heterocyclic rings are inclined at the
angle of 22.7(2)◦. However, the most pronounced difference concerns the interaction between the
molecular Ag(I) cation and counter ions. In complex 1, the nitrate anion binds strongly to the silver
center, whereas, in complex 2, the perchlorate anion interacts very weakly.
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Figure 2. Molecular structures of Ag(I) complexes with miconazole and nitrate (1) (a) and perchlorate
(2) (b) counter ions. The ellipsoids are drawn at the 30% (1) and 50% (2) probability level. The B-parts
of the disordered atoms are omitted for clarity. Symmetry codes: for 1 (i) 1 − x, y, 12 − z; for 2 (i) 1 − x, y,
1
2 − z.
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Table 2. Crystallographic data for 1 and 2.
1 2
Empirical formula C36H28AgCl8N5O5 C36H28AgCl8N4O2·ClO4
Formula weight 1002.10 1039.54
Crystal system Monoclinic Monoclinic
Space group C2/c C2/c
a (Å) 25.8806(15) 15.6640(6)
b (Å) 8.0278(5) 8.5524(3)
c (Å) 19.8754(15) 30.2426(12)
α (◦) 90.000 90.000
β (◦) 103.273(7) 97.335(4)
γ (◦) 90.000 90.000
V (Å3) 4019.1(5) 4018.3(3)
Z 4 4
T (K) 293(1) 100(1)
F (000) 2008 2080
Dx (g·cm−3) 1.656 1.718
µ (mm−1) 9.33 1.15
Wavelength (Å) 1.54184 0.71073
θ range (◦) 3.5–68.0 3.0–29.0
Measured reflections 8223 19996
Unique reflections 3561 5346
Observed reflections [I > 2σ (I)] 2035 4518
Completeness to θmax (%) 97.2 99.8
Parameters/restraints 269/14 251/1
R [F2 > 2σ (F2)] 0.059 0.054
wR (all data) 0.181 0.143
S 1.06 1.06
Table 3. Geometry (Å, ◦) around silver(I) in complexes 1 and 2.
1 2 1 2
Bond Lengths Bond Angles
Ag–N 2.181(5) 2.068(3) N–Ag–Ni 152.4(3) 175.81(16)
Ag–Ni 2.181(5) 2.068(3) N–Ag–Onitrate 123.4(4) -
Ag–Onitrate 2.510(15) - Ni–Ag1–Onitrate 84.2(4) -
Ag–Ochlorate - 3.140(3) N–Ag–Ochlorate - 99.91(17)
Ag–Clii 3.189(2) - Ni–Ag–Ochlorate - 84.02(17)
Symmetry codes: for 1 (i) 1 − x, y, 12 − z; (ii) 1 − x, −y, 1 − z; for 2 (i) 1 − x, y, 12 − z.
The analysis of close contacts in the structure 1 revealed the Ag· · ·Cl intermolecular interactions
which complement the coordination of Ag(I). Figure 3 demonstrates the molecular chains formed by
a propagation of Ag· · ·Cl contacts along the crystallographic c axis. These chains are additionally
stabilized by the C15–H15· · ·pi (heterocyclic ring) intermolecular interaction. The geometries of
intermolecular interactions are listed in Table 3. The C–H· · ·O hydrogen bonds link the miconazole
ligands with nitrate anions along the b axis (Figure 4a). Finally, molecular layers bc are observed.
There are aromatic pi· · ·pi stacking interactions of Cg1· · ·Cg2 (Supplementary Materials Table S1)
between adjacent layers; however, pi-electrons of the dichlorophenyl rings C13–C18 (Cg3· · ·Cg3)
interact with each other within the layer.
As far as structure 2 is concerned, there are no additional close contacts with the silver center.
Similarly to structure 1, C–H· · ·O hydrogen bonds are observed between the miconazole ligands and
perchlorate anions (Table 4, Figure 4b). The propagation of weak hydrogen bonds leads to the formation
of molecular ab layers (Supplementary Materials Figure S4). The short contacts of Cl3· · ·Cl3 (−x,
1 − y, 1 − z) are observed between these layers. Aromatic pi· · ·pi interactions are also found (Table S1,
Supplementary Materials) for Cg3· · ·Cg2 within the layer and Cg3· · ·Cg3 between the adjacent layers.
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Figure 4. A scheme C–H· · ·O of hydrogen bonds (blue dotted) between cations and anions of 1 (a)
and 2 (b). Red dotted show weak Ag· · ·O contacts between cations and anions of 2 (b). In both cases,
hydrogen atoms not involved in H-bonds are omitted for clarity. Symmetry codes for 1: (i) 1 − x, y,
1
2 − z; (iv) x, −1 + y, z; (v) 1 − x,−1 + y, 12 − z. Symmetry codes for 2: (i) 1 − x, y, 12 − z; (ii) − 12 + x, − 12 + y,
z; (iii) x, −y, − 12 + z; (iv) 1 − x, −1 + y, 12 − z.
Table 4. Hydrogen bonding geometry (Å, ◦) for silver(I) complexes 1 and 2.
H–Bond D–H H· · ·A D· · ·A D–H· · ·A
1
C3–H3· · ·O3iv 0.93 2.36 3.202(8) 150
C17–H17· · ·O2Aiv 0.93 2.64 3.436(19) 144
C17–H17· · ·O2Biv 0.93 2.53 3.363(19) 149
C18–H18· · ·O2Av 0.93 2.67 3.347(19) 130
C18–H18· · ·O2Bv 0.93 2.60 3.415(19) 146
C15–H15· · ·Cg(1)ii 0.93 2.94 3.798(8) 155
2
C2–H2A· · ·O2ii 0.99 2.67 3.531(5) 145
C2–H2A· · ·O3Aiii 0.99 2.70 3.474(7) 135
C2–H2A· · ·O3Bii 0.99 2.52 3.471(7) 161
C2–H2A· · ·O3Biii 0.99 2.54 3.388(7) 144
C3–H3· · ·O2i 0.95 2.51 3.356(5) 136
C4–H4· · ·O3Aiv 0.95 2.65 3.579(7) 166
C4–H4· · ·O3Biv 0.95 2.55 3.372(7) 145
In 1: Cg(1)—center of gravity of the heterocyclic ring. Symmetry codes: 1 (ii) 1 − x, − y, 1 − z; (iv) x, − 1 + y, z;
(v) 1 − x, − 1 + y, 12 − z; 2 (i) 1 − x, y, 12 − z (ii) − 12 + x, − 12 + y, z; (iii) 12 − x, − 12 + y, 12 − z; (iv) x, − 1 + y, z.
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2.6. QTAIM Analysis
Two types of chemical bonds were analyzed: Ag–N between the silver cation and nitrogen
from azole ligands, and Ag–O (or F) between silver(I) and counter anions (NO3−, ClO4−, CF3COO−,
CH3SO3−, BF4−).
The results in Table 5 are listed according to ascending bond length. It can be seen that the silver(I)
complexes of metronidazole (MTZ = 1-(2-hydroxyethyl)-2-methyl-5-nitro-1H-imidazole) [20] have
quite similar bond lengths and they are located in the middle of the table, whereas the miconazole
complexes are found on the top and the bottom of the table. Silver–nitrogen distances range from
2.06Å to 2.18Å, both extreme values corresponding to the analyzed complexes of silver with the
miconazole ligand.
Table 5. Quantum Theory of Atoms in Molecules (QTAIM) bonding indicators for Ag−N and Ag−O/F
for silver(I) complexes with metronidazole and miconazole ligands and different counter ions.
d N–Ag–N/O ρbcp ∇2ρbcp ε G/ρbcp H/ρbcp δ
Ag–N
(2) MCZ-ClO4− 2.068 176 0.68 9.3 0.05 1.23 −0.28 0.66
MTZ-BF4− 2.110 175 0.62 8.5 0.05 1.21 −0.25 0.62
MTZ-ClO4− 2.126 172 0.60 8.2 0.05 1.20 −0.24 0.59
MTZ-NO3− 2.147 165 0.57 7.9 0.04 1.19 −0.22 0.59
MTZ-CF3COO− 2.160 163 0.55 7.7 0.03 1.19 −0.21 0.57
MTZ-CH3SO3− 2.165 170 0.55 7.6 0.04 1.19 −0.21 0.56
(1) MCZ-NO3− 2.181 152 0.53 7.5 0.02 1.20 −0.20 0.55
Ag–O d N−Ag−Oanion ρbcp ∇2ρbcp ε G/ρbcp H/ρbcp δ
MTZ-CF3COO− 2.480 112 0.25 3.6 0.04 1.03 −0.01 0.29
(1) MCZ-NO3− 2.510 123 0.22 3.6 0.04 1.12 0.00 0.17
MTZ-CH3SO3− 2.577 100 0.20 2.8 0.07 0.97 −0.01 0.23
MTZ-ClO4− 2.660 91 0.17 2.3 0.07 0.93 0.01 0.18
MTZ-NO3− 2.669 112 0.17 2.2 0.07 0.91 0.01 0.19
(2) MCZ-ClO4− 3.140 100 0.07 0.8 0.07 0.75 0.03 0.07
Ag–F d N−Ag−Fanion ρbcp ∇2ρbcp ε G/ρbcp H/ρbcp δ
MTZ-BF4− 2.885 0.09 1.2 0.03 0.92 0.04 0.09
As the length of the bonds (d) increases, the N–Ag–N angle decreases; thus, the linearly attached
ligands tend to characterize short distances. The relatively small electron density values (ρbcp) reflect
geometric changes. The positive sign of the Laplacian (∇2ρbcp) points toward an electrostatic donor
interaction, which is in agreement with the quite high values of the degree of iconicity (G/ρbcp).
The degree of covalency (H/ρbcp ratio) also seems to be small. Ellipticity (ε) remains almost unchanged,
close to 0. On the other hand, delocalization index values (δ) ranging from 0.66 to 0.55 indicat the quite
high covalent contribution for Ag–N bonds.
In the case of Ag–Oanion interactions, the geometric trends are inverse to Ag–N bonds. Here, the
miconazole–silver(I) complex with nitrate is found at the top of Table 5, whereas the miconazole–silver(I)
complex with perchlorate is at the bottom of Table 5. In the former structures, the anion is connected
very weakly with the metal. All parameters clearly show the dominant ionic character of all Ag–Oanion
interactions, where the covalent contribution is negligible. In most cases, the delocalization index
is around 0.2. Interestingly, a reasonable sharing of the electron pair (δ) is observed in the case of
CF3COO and CH3SO3 anions in complexes with metronidazole Ag(I) complexes. The miconazole
Ag(I) complex with perchlorate anion (2) differs from the others. It exhibits the weakest interaction
between cationic and anionic molecules; the electron density and its Laplacian at the bond critical
point of this interaction are close to zero. The perchlorate anion in the Ag(I) complex structure with
the miconazole ligand behavs similarly to the BF4− counter ion in the metronidazole Ag(I) complex.
In both cases, there is no sharing of the electron pair.
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2.7. Cytotoxic Activity
The cytotoxic activity of the compounds was investigated in vitro against human hepatocellular
carcinoma HepG2 cells and non-tumorigenic murine Balb/c 3T3 fibroblasts using four biochemical
endpoints: mitochondrial (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT)
assay) and lysosomal (neutral red uptake (NRU) assay) activity, total protein content (TPC assay),
and cellular membrane integrity (lactate dehydrogenase (LDH) assay) after 72 h of exposition. Human
HepG2 cells were more sensitive to the compounds than murine Balb/c 3T3 fibroblasts. The studied
complexes with miconazole significantly inhibited all endpoints of the HepG2 cells starting with the
0.1 µM concentration (Figure 5). In the case of Balb/c 3T3 fibroblasts, at the higher concentration of
1.0 µM, the effects in MTT, NRU, and TPC assays were recorded (Figure 5). The study complexes
in 0.1 µM concentration affected the cellular membrane (LDH assay), leading to disintegration of
hepatoma cells and fibroblasts (Figure 5). The obtained cytotoxic concentrations (IC20 and IC50) values
are shown in Table 6. The concentrations of the study complexes (IC20) necessary for 20% inhibition
of hepatoma cell (HepG2) viability were about two-fold lower compared with values obtained for
fibroblasts (Table 6). However, these values were higher compared to IC20 values for cisplatin on
HepG2 cells (Table 6). The IC50 values for miconazole silver(I) complexes in all the assays used were
~0.5 µM in Balb/c 3T3 fibroblasts (Table 6). In the case of HepG2 cells, the IC50 values were lower
compared to those obtained for fibroblasts as with the IC20 values. The lowest IC50 values were
obtained for cancer cells in the LDH assay. It is worth noting that IC50 values in the LDH assay
were lower for the [Ag(MCZ)2ClO4] complex (0.26 µM) compared with values for [Ag(MCZ)2NO3]
(0.40 µM). However, these IC50 values were higher compared to cisplatin (0.01 µM). The IC50 values
for cisplatin were higher than 1 µM in the MTT, NRU, and TPC assays for HepG2 cells and in all used
assays for fibroblasts (Table 6). The studied silver(I) salts and MCZ were not toxic to the tested cell
lines (Supplementary Materials Figure S5). The IC50 values were not calculated for these compounds
in both cellular models (up to the highest concentration, 1 µM) (Table 6).
Table 6. Cytotoxicity concentrations (IC20 and IC50, µM) determined in HepG2 Balb/c 3T3 cells by the
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), neutral red uptake (NRU),
total protein content (TPC), and lactate dehydrogenase (LDH) assays after 72 h of exposure to the
studied compounds; data are presented as means (n = 3) ± SD.
HepG2 Balb/c 3T3
MTT NRU TPC LDH MTT NRU TPC LDH
IC20
[Ag(MCZ)2NO3] 0.14 a ± 0.02 0.16 a ± 0.01 0.09 a ± 0.04 0.08 a ± 0.01 0.25 b ± 0.03 0.23 b ± 0.02 0.22 b ± 0.04 0.18 b ± 0.01
[Ag(MCZ)2ClO4] 0.12 a ± 0.02 0.14 a ± 0.02 0.10 a ± 0.01 0.06 a ± 0.01 0.24 b ± 0.01 0.26 b ± 0.03 0.21 b ± 0.01 0.22 b ± 0.03
Miconazole > 1 > 1 > 1 > 1 > 1 > 1 > 1 > 1
AgNO3 > 1 > 1 > 1 > 1 > 1 > 1 > 1 > 1
AgClO4 > 1 > 1 > 1 > 1 > 1 > 1 > 1 > 1
Cisplatin < 0.0001 < 0.0001 < 0.0001 0.01 ± 0.001 > 1 > 1 > 1 > 1
IC50
[Ag(MCZ)2NO3] 0.46 a ± 0.01 0.47 a ± 0.02 0.45 a ± 0.02 0.40 a ± 0.01 0.54 b ± 0.02 0.54 b ± 0.01 0.53 b ± 0.01 0.52 b ± 0.04
[Ag(MCZ)2ClO4] 0.45 a ± 0.01 0.46 a ± 0.01 0.44 a ± 0.02 0.26 a ± 0.08 0.53 b ± 0.01 0.53 b ± 0.02 0.52 b ± 0.02 0.51 b ± 0.03
Miconazole > 1 > 1 > 1 > 1 > 1 > 1 > 1 > 1
AgNO3 > 1 > 1 > 1 > 1 > 1 > 1 > 1 > 1
AgClO4 > 1 > 1 > 1 > 1 > 1 > 1 > 1 > 1
Cisplatin > 1 > 1 > 1 0.01 ± 0.001 > 1 > 1 > 1 > 1
The different letters (a, b) within lines indicate significant differences (p ≤ 0.05) between the cell cultures for the
corresponding assay; <0.0001—the IC20 value was under 0.0001 µM (the lowest concentration tested); >1—the IC20
or IC50 value was over 1 µM (the highest concentration tested).
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Balb/c 3T3 fibroblasts measured by MTT, NRU, TPC, and LDH assays. The data are presented as means
(n = 3) ± SD (* p ≤ 0.05).
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Recent evidence suggests that triazoles and miconazole exhibit antiproliferative effects, and they
can be modified on their 1,2,4-triazole nucleus to generate different types of anticancer agents.
Miconazole was also shown to be an effective anticancer drug. It was found to inhibit the proliferation
of human cancer cells at a concentration up 10 µM, e.g., breast, bladder, and colorectal cancer cell lines,
as well as acute myelogenous leukemia and osteosarcoma cells [56]. In both cases of the complexes
[Ag(MCZ)2ClO4] and [Ag(MCZ)2NO3], the coordination of the metal to the ligand (MCZ) increased
their cytotoxic activity, which was higher compared to the anticancer activity of cisplatin.
In our previous studies, we reported on the cytotoxicity of the compound [Ag(MTZ)2NO3] [57].
The study showed that non-tumorigenic murine Balb/c 3T3 fibroblasts were more sensitive to the test
complex compared to HepG2 human liver cancer cells. On the other hand, the results in this paper for
the compound [Ag(MCZ)2NO3] indicated the better efficacy of elimination of HepG2 cancer cells and
lower toxicity to Balb/c 3T3 fibroblasts than the silver(I) complex of metronidazole. In addition, the
[Ag(MCZ)2NO3] complex compared to [Ag(MTZ)2NO3] began to destroy HepG2 liver cancer cells at
lower concentrations, silver(I) complexes of miconazole were up to tenfold more cytotoxic to cancer
cells compared to the silver(I) complex of metronidazole [Ag(MTZ)2NO3] [57]. However, the model of
action on cancer cells was the same for studied silver(I) complexes of imidazole derivatives, leading
to the damage cell membrane. A comparison of both complexes suggests that the choice of ligand
substantially contributed to the increased compound toxicity to tumor cells. In this case, the exchange
of the ligand improved the anti-tumor properties.
3. Materials and Methods
3.1. Chemicals and Reagents
Miconazole (CAS: 22916-47-8; molecular weight 416.1 g/mol) was purchased from Alfa Aesar
(Kandel, Germany). Silver nitrate (CAS: 7761-88-8; molecular weight: 169 g/mol), silver perchlorate
(CAS: 7783-93-9; molecular weight: 207.3 g/mol), and cisplatin (CAS: 15663-27-1; molecular weight:
300 g/mol) were purchased from Sigma-Aldrich (Poznan´, Poland). Triton X-100, trypan blue, dimethyl
sulfoxide (DMSO), fetal bovine serum (FBS), bovine calf serum (BCS), neutral red dye (NR),
Coomassie brilliant blue R-250 dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), trypsin-ethylenedinitrilotetraacetic acid (EDTA), and antibiotic solution (10,000 U/mL of
penicillin, 10 mg/mL of streptomycin) were purchased from Sigma–Aldrich Co. (Poznan´, Poland).
All other chemicals were purchased from commercial suppliers and were of the highest
available purity.
3.2. Synthetic Procedures
3.2.1. Synthesis of [Ag(Miconazole)2NO3] (1)
Miconazole (MCZ) (1 mmol, 0.416 g) was dissolved in 10 mL of ethanol. AgNO3 solution (0.5 mmol,
0.085 g) in 10 mL of ethanol was added into the miconazole ethanolic solution and stirred for 24 h
at room temperature. The white solid that was formed was filtered off and washed with portions of
diethyl ether. The white crystals suitable for X-ray diffraction were grown from pure acetonitrile at
room temperature. Molecular weight (MW) 1002.05 g/mol; yield: (0.40 g, 80%); melting point (m.p.)
153–155 ◦C. ESI-MS (methanol) m/z: 938.87 [Ag(MCZ)2]+. El. anal. Measured (calc.%): C—43.16
(43.15); H—2.47 (2.81); N—6.98 (6.99). 1H-NMR (600 MHz, CDCl3) δ (ppm): 4.13 (m, 4H, 2 × N—CH2),
4.16 (m, 2H, 2 × CH—O), 4.55 (s, 4H, 2 × CH2—O), 7.08 (s, 2H, 2 × CH=C), 7.29 (s, 2H, 2 × CH=C),
7.32 (m, 2H, 2 × CH—N), 7.34 (m, 2H, 2 × CH—N), 7.36 (m, 2H, 2 × CH=C), 7.37 (s, 2H, 2 × CH=C),
7.40 (s, 2H, 2 × CH=C), 7.49 (d, 2H, 2 × CH=C, J=1.90 Hz), 8.08 (s, 2H, 2 × CH—N). IR (KBr) νmax/cm−1:
3123, 3100, 2977 (C—H), 1722 (C=N), 1588, 1563 (C—C, C=C), 1518 (C—C, C—H, C=C), 1471 (C—H,
C=C), 1431 (C=C), 1380 (NO3), 1245, 1183, 1118, 1098 (C—O—C), 840, 831, 820 (C—Cl).
Int. J. Mol. Sci. 2020, 21, 3629 12 of 18
3.2.2. Synthesis of [Ag(Miconazole)2ClO4] (2)
AgClO4 solution (0.5 mmol, 0.104 g) in 10 mL of ethanol was added to the miconazole ethanolic
solution (miconazole (1 mmol, 0.416 g) in 10 mL of ethanol). Next, the whole mixture was stirred for
24 h at room temperature. The final product was filtered off and washed with portions of diethyl ether.
The white crystals suitable for X-ray diffraction were grown from pure acetonitrile at room temperature.
MW 1038.92 g/mol; yield: (0.48 g, 92%); m.p. 175–177 ◦C. ESI-MS (methanol) m/z: 938.87 [Ag(MCZ)2]+.
El. anal. Measured (calc.%): C—41.68 (41.62); H—2.36 (2.71); N—5.41 (5.40). 1H-NMR (600 MHz,
CDCl3) δ (ppm): 4.16 (m, 4H, 2 × N—CH2), 4.19 (m, 2H, 2 × CH—O), 4.56 (s, 4H, 2 × CH2—O), 7.09 (s,
2H, 2 × CH=C), 7.29 (s, 2H, 2 × CH=C), 7.33 (m, 2H, 2 × CH—N), 7.34 (m, 2H, 2 × CH—N), 7.35 (m,
2H, 2 × CH=C), 7.39 (s, 2H, 2 × CH=C), 7.40 (s, 2H, 2 × CH=C), 7.49 (d, 2H, 2 × CH=C, J=1.90 Hz),
8.20 (s, 2H, 2 × CH—N). IR (KBr) νmax/cm−1: 3125, 3092, 2972 (C—H) 1727 (C=N), 1590, 1562 (C—C,
C=C), 1526 (C—C, C—H, C=C), 1470 (C—H, C=C), 1437 (C=C), 1248, 1139, 1119, 1095 (C—O—C),
1078 (ClO4), 848, 816 (C—Cl).
3.3. Light Stability of Compounds 1 and 2
The light stability of the [Ag(MCZ)2NO3] and [Ag(MCZ)2ClO4] complexes, as well as silver(I)
salts, was studied in normal daylight in air atmosphere and in the dark [20,55]. The complexes were
dissolved in acetonitrile, while the silver(I) salts were dissolved in water. The concentration of each
solution was 0.05 mol/L. For comparative purposes, the solutions of the complexes and silver(I) salts
were applied onto various substrates (tissue paper, paper, glass, and synthetic leather) in the amount
of 2.5 µmol (50 µL of the solution).
Stability was monitored visually for 108 h making image documentation after 0, 1, 4, 18, 24, 40, 48,
52, 60, 84, and 108 h. The photos of the samples are shown in the (Supplementary Materials Figure S3).
3.4. X-ray Single-Crystal Diffraction
The crystallographic data were collected using a SuperNova diffractometer with an Atlas detector
using CuKα at 293 K for 1 and MoKα radiation at 100 K for 2. Data reduction and multi-scan absorption
correction were performed. The data for both complexes were collected and processed using CrysAlis
PRO [58]. The structures were solved with SHELXT [59] and refined with SHELXL-2018/3 [60].
All non-hydrogen atoms were refined anisotropically. All (C)–H atoms of metronidazole ligands
were calculated to their idealized positions and refined as riding atoms with isotropic displacement
parameters Uiso(H) = 1.2Ueq(C). One oxygen atom (O2) in the nitrate group and one chlorine atom
(Cl1) of structure 1 were found to be disordered and refined in two alternative positions with the final
site occupation factors equal to 0.5. In structure 2, one oxygen atom (O3) in the perchlorate group was
also refined as disordered (0.5). Within the disordered parts, geometrical similarity restraints were
applied to some N–O, C–Cl bonds in 1 and Cl–O bonds in 2 using the SADI instruction.
3.5. QTAIM
Single-point calculations of 1–2 and five Ag(I) complexes of metronidazole [20] with the X-ray
single-crystal coordinates (the distances to H-atoms were normalized [61]) were carried out using
Gaussian09 [62] at the B3PW91 level [63,64] using effective core potentials along with the associated
VTZ basis set for Ag [65,66] and 6-311+G(d) basis elsewhere. Subsequently, the wave function files
were used for a topological analysis of the electron density with AIMALL [67].
3.6. Chemistry
The 1H-NMR spectra were recorded with a Bruker Advance III 600 MHz spectrophotometer
(Bruker Corporation, Billerica, MA, USA) in CDCl3 at room temperature. Infrared spectra were
recorded in the range of 4000–400 cm−1 on a Bruker Alpha-T (Bruker Corporation, Billerica, MA,
USA) using KBr pellets. Electrospray ionization mass spectra (ESI-MS) were registered in positive
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ion mode on a Varian 500-MS LC Trap (Varian Inc., Palo Alto, CA, USA). Elemental analyses (C, H,
N) were performed at the Faculty of Pharmacy (Medical University of Lodz, Poland) with a Perkin
Elmer 2400 analyzer (PerkinElmer, Waltham, MA, USA). Melting points of all the compounds were
determined with a Böetius apparatus.
3.7. Cell Culture and Cytotoxicity Assessment
3.7.1. Cell Culture
The human hepatoma cell line (HepG2) was purchased from the American Type Culture Collection
(ATCC HB-8065). These cells were cultured in Minimum Essential Medium Eagle (MEME) (ATCC).
The murine fibroblast cell line (Balb/c 3T3 clone A31) was purchased from the American Type Culture
Collection (ATCC CCL-163), and the cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) (ATCC). The media were supplemented with 10% BCS (Balb/c 3T3), 10% FBS (HepG2),
1% l-glutamine, and 1% antibiotic solution. The cells were maintained in 75-cm2 cell culture flasks
(NUNC, Roskilde, Denmark) in a humidified incubator, NuAire (Plymouth, MN, USA) at 37 ◦C and 5%
CO2. The medium was refreshed every two days and the cells were trypsinized by 0.25% trypsin–0.02%
EDTA after reaching 70–80% confluence. Then, cell suspensions at a density of 2 × 105 cells/mL (HepG2)
and 5 × 104 cells/mL (Balb/c 3T3) were transferred to 96-well plates (100 µL/well) and incubated for
24 h before the exposure to the studied compounds.
3.7.2. Compounds Preparation and Exposure
Stock solutions of ligands, cisplatin, and silver(I) miconazole complexes were dissolved in DMSO
and diluted with the culture medium to obtain a concentration range from 10−4 to 100 µM. The final
concentration of DMSO in the medium was 0.1% and had no influence on cell growth. The medium
used for test solutions and controls did not contain serum and antibiotics. As a control, cultured cells
were grown in the absence of the studied compounds. Each concentration was tested in six replicates in
three independent experiments. Cytotoxicity was assessed after 72 h of cell exposure to the compounds
in darkness. The medium was not changed during the incubation time.
3.7.3. Cytotoxicity Assessment
MTT assay. The metabolic activity of living cells was assessed by the measurement of the activity
of dehydrogenases [38]. After incubation of the cells with the study compound, 10 µL of the MTT
solution (5 mg/mL in phosphate buffered saline (PBS)) was added to each well of the 96-well plate
and incubated. After 3 h, the MTT solution was removed, and intracellular formazan crystals were
dissolved in 100 µL DMSO. The plate was shaken for 15 min at room temperature and transferred to a
microplate reader (Synergy HTX multi-mode reader (BioTek® Instruments Inc., Winooski, VT, USA))
to measure the absorbance at 570 nm, using a blank as a reference. Cytotoxicity was expressed as a
percentage of the negative control (0.1% DMSO) [33].
NRU assay. This method is based on staining living cells with neutral red which readily diffuses
through the plasma membrane and accumulates in lysosomes [36]. After the incubation, the medium
containing the drug was removed, and the cells were washed with PBS. Then, 100 µL/well of NR
solution (50 µg/mL) was added for 3 h. After this time, the cells were washed with PBS. The dye
from viable cells was released by extraction with a mixture of acetic acid, ethanol, and water (1:50:49,
v:v:v). After 10 min of shaking, the absorbance of the dissolved NR was measured using a Synergy
HTX multi-mode reader (BioTek® Instruments Inc., Winooski, VT, USA) at 540 nm using a blank as a
reference. Cytotoxicity was expressed as a percentage of the negative control (0.1% DMSO) [33].
TPC assay. The assay was based upon staining total cellular protein (proliferation) [37]. After the
incubation, the medium containing drug was removed and 100 µL of Coomassie brilliant blue R-250
dye was added to each well. The plate was shaken for 10 min. Then, the stain was removed and
the cells were rinsed twice with 100 µL of washing solution (glacial acetic acid/ethanol/water, 5:10:85,
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v:v:v). After that, 100 µL of the desorbing solution (1 M potassium acetate) was added, and plates were
shaken again for 10 min. The absorbance was measured at 595 nm in a microplate reader (Synergy
HTX multi-mode reader (BioTek® Instruments Inc., Winooski, VT, USA)) using a blank as a reference.
Cytotoxicity was expressed as a percentage of the negative control (0.1% DMSO) [33].
LDH leakage assay. The integrity of the plasma membrane was assessed through the test of
lactate dehydrogenase (LDH) release [39], which was monitored using the commercially available
Cytotoxicity Detection Kit (LDH) (Roche Diagnostics, Warsaw, Poland). The medium (100 µL/well)
without cells was transferred into the corresponding wells of an optically clear 96-well flat-bottom
microplate, and 100 µL of reaction mixture was added to each well. Then, the plates were incubated for
30 min at room temperature in darkness. After that time, 50 µL/well of 1 M HCl was added to stop the
reaction. The absorbance was measured at 492 nm in a microplate reader (Synergy HTX multi-mode
reader (BioTek® Instruments Inc., Winooski, VT, USA)) using a blank as a reference [33].
3.7.4. Statistical Analysis
The study was performed in three independent experiments. The obtained results are presented as
mean values ± SD (standard deviation). Assessment of the cytotoxicity data used a one-way analysis of
variance (ANOVA) followed by Dunnett’s post-hoc test, which was applied to determine significance
relative to the negative control. The cytotoxicity concentration (IC20 and IC50) necessary for 20% and
50% inhibition of cell viability, respectively, by the drug was calculated using GraphPad Prism 5.0.
Statistical comparisons among IC50 values were performed by the analysis of variance (ANOVA)
followed by the Tukey test, and differences were considered statistically significant at p ≤ 0.05.
4. Conclusions
This paper proposed a facile and convenient method for synthesis of silver(I) complexes using
miconazole and silver(I) nitrate and silver(I) perchlorate. The developed direct method of synthesis can
be considered as simple, fast, and accurate. The present work demonstrated the use of two medicines,
i.e., miconazole and silver(I) nitrate, in the direct synthesis of the complexes for the evaluation of their
cytotoxic activity.
The results of our research show that complexes of silver(I) ions with the biologically active ligand
miconazole inhibit the growth of HepG2 cancer cells.
The tested compounds were much more toxic to human cancer cells compared to the free ligand.
In addition, the obtained silver(I) complexes more powerfully eliminated HepG2 cancer cells than
cisplatin. Miconazole and silver salts were not toxic to the cell lines tested. Moreover, hepatic cancer
HepG2 cells were more sensitive to the action of silver(I) complexes than the fibroblasts. The results
indicated better efficiency of elimination of HepG2 cancer cells and lower toxicity to Balb/c 3T3 fibroblasts
for [Ag(MCZ)2NO3] compared to the silver(I) complex of metronidazole [Ag(MTZ)2NO3] [57].
Based on the chemical bonding analysis, it seems that the different molecular conformations of
the analyzed complexes and the strength of interaction between the cation and anion did not affect
the cytotoxic activity of the complex compounds, since they exhibited a similar effect on cancer cells,
leading to the disintegration of cellular membranes. The new compounds could be probable candidates
as promising therapeutic agents for the treatment of hepatocellular carcinoma, which should attract
further studies.
Miconazole silver(I) complexes may be considered as a therapeutic option in skin infections
caused by fungal strains, as well as by bacteria strains that are resistant to antibiotics. After all, we
recently reported [68] the significant effect of treatment of patients with ocular rosacea with a silver(I)
complex of metronidazole, which might be an alternative method of acne rosacea treatment.
Evaluation of the microbiological activity of silver(I) miconazole complexes will be the subject of
our further study.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/10/
3629/s1.
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